(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2020 (10.09.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/180850 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/26* (2006.01)
A61K 9/08 (2006.01) *A61K 47/42* (2017.01)
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2020/020752

(22) International Filing Date:
03 March 2020 (03.03.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/813,843 05 March 2019 (05.03.2019) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill Rover Road, Tarrytown, New York 10591 (US).

(72) Inventors: **KIM, Dorothy**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MARLOW, Michael**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **CAPLAN, Jonathan S.**; Kramer Levin Naftalis & Frankel LLP, 1177 Avenue of the Americas, New York, New York 10036 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: HUMAN SERUM ALBUMIN IN FORMULATIONS

FIG. 1



(57) Abstract: Drug formulations and methods for removing, reducing, or preventing the formation of fatty acid particles in drug formulations are provided.

WO 2020/180850 A1